The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prerandomization factors and utilization of neoadjuvant chemotherapy in a clinical trial of extended versus standard pelvic lymphadenectomy at the time of radical cystectomy for bladder cancer.
Seth P. Lerner
No relevant relationships to disclose
Hongli Li
No relevant relationships to disclose
Robert Scott Svatek
No relevant relationships to disclose
Theresa M. Koppie
No relevant relationships to disclose
Ajjai Shivaram Alva
No relevant relationships to disclose
Francisco G. La Rosa
No relevant relationships to disclose
Rick Bangs
No relevant relationships to disclose
Sumanta Kumar Pal
No relevant relationships to disclose
Siamak Daneshmand
No relevant relationships to disclose
Adam S. Kibel
No relevant relationships to disclose
Daniel J. Canter
No relevant relationships to disclose
Catherine M. Tangen
No relevant relationships to disclose
Ian Murchie Thompson
No relevant relationships to disclose